- $24.39bn
- $20.57bn
- $5.14bn
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Brief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Mirum rises on FDA nod for rare bone disorder drug
U.S. RESEARCH ROUNDUP-Chevron, Mobility Global, Tesla
Brief: FDA Approves Atebrioz For Fibrodysplasia Ossificans Progressiva In Adults, Pediatric Patients
US FDA approves Mirum's drug for rare bone disorder (updated)
US FDA approves Mirum's drug for rare bone disorder
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Mid-cap drugmakers face limited impact from Trump drug pricing deals, analysts say
Brief: Incyte Announces Agreement With CMS To Improve Medicine Access
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)